Skip to main content
. 2010 Mar-Apr;2(2):137–147. doi: 10.4161/mabs.2.2.11271

Table 1.

Phase 2 study in RA

CDP870-00425 Phase 2 trial: Active RA patients (n = 203)
SC CZP or placebo every 4 weeks for 12 weeks.
Endpoints (week 12) Placebo CZP 50 mg CZP 100 mg CZP 200 mg CZP 400 mg
ACR20 15% 21% 20% 34% 60%
ACR50 0% 8% 5% 17% 40%
ACR70 0% 5% 3% 7% 29%

RA, rheumatoid arthritis; SC, subcutaneous; CZP, certolizumab pegol; ACR, American College of Rheumatology.